Comparing Peak Bio (NASDAQ:PKBO) & Adaptimmune Therapeutics (NASDAQ:ADAP)

Adaptimmune Therapeutics (NASDAQ:ADAP) and Peak Bio (NASDAQ:PKBO) are both small-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.

Earnings & Valuation

This table compares Adaptimmune Therapeutics and Peak Bio”s revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Adaptimmune Therapeutics	$141.46 million	1.92	-$113.87 million	($0.74)	-1.49
Peak Bio	$370,000.00	8.75	-$12.83 million	N/A	N/A

Peak Bio has lower revenue, but higher earnings than Adaptimmune Therapeutics.

Institutional and Insider Ownership

31.4% of Adaptimmune Therapeutics shares are held by institutional investors. 12.4% of Adaptimmune Therapeutics shares are held by company insiders. Comparatively, 19.9% of Peak Bio shares are held by company insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Volatility & Risk

Adaptimmune Therapeutics has a beta of 2.21, indicating that its share price is 121% more volatile than the S&P 500. Comparatively, Peak Bio has a beta of 0.21, indicating that its share price is 79% less volatile than the S&P 500.

Analyst Ratings

This is a summary of current recommendations and price targets for Adaptimmune Therapeutics and Peak Bio, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Adaptimmune Therapeutics	0	0	3	0	3.00
Peak Bio	0	0	0	0	N/A

Adaptimmune Therapeutics currently has a consensus target price of $3.38, suggesting a potential upside of 207.58%. Given Adaptimmune Therapeutics’ higher probable upside, research analysts clearly believe Adaptimmune Therapeutics is more favorable than Peak Bio.

Profitability

This table compares Adaptimmune Therapeutics and Peak Bio’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Adaptimmune Therapeutics	-51.25%	-116.80%	-25.02%
Peak Bio	N/A	N/A	-253.92%

Summary

Adaptimmune Therapeutics beats Peak Bio on 6 of the 11 factors compared between the two stocks.

About Adaptimmune Therapeutics

Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.

About Peak Bio

Peak Bio, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for the treatment of patients with inflammatory, cancer, and rare and specialty diseases. The company's lead product candidate is PHP-303, which is in phase 2 clinical study for the treatment of alpha-1 antitrypsin deficiency and acute respiratory distress syndrome. It also develops Trop2 PH1, an antibody-drug-conjugate for solid tumors. The company was founded in 2020 and is based in Pleasanton, California.